Eyerising International’s at-home device for myopia control is now listed by the Australian Therapeutic Goods Administration (TGA).
Already approved for sale in Europe, the Eyerising Myopia Management Device utilises patented technology, delivering repeated low-level red-light (RLRL) therapy. By gently stimulating blood flow in the ocular fundus, the device is designed to alleviate scleral hypoxia and control axial lengthening, both known causes of myopia.
Eyerising maintains a key advantage of this therapy is convenience, since children can use it at home, under parental supervision, for just three minutes, twice a day, five days a week. This approach offers potential benefits for managing myopia earlier and provides additional treatment options for clinicians, said the company. The device’s simple touchscreen control makes it suitable for children as young as three years old.
